TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

August 7, 2024

https://www.globenewswire.com/news-release/2024/08/06/2925031/0/en/TFF-Pharmaceuticals-Provides-Continued-Positive-Outcomes-from-Tacrolimus-Inhalation-Powder-TFF-TAC-Phase-2-Trial-for-the-Prevention-of-Lung-Transplant-Rejection.html

Patient enrollment has accelerated, now with 13 patients enrolled in trial

TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood levels — leading to diminished drug burden

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.